The US investment firm has acquired the advanced therapies units of WuXi AppTec including its Oxford-based Oxgene arm.
US investment firm Altaris has acquired the British and US operations of Chinese pharmaceutical research outsourcing company WuXi AppTec’s Advanced Therapies Unit. Financial terms have not been disclosed but the transaction is expected to close in the first half of the year.
After the transaction completes, Advanced Therapies will be renamed and headquartered in the US, operating as a fully owned portfolio company of Altaris.
Advanced Therapies aims to be an expert in complete cell therapy outsourcing, including viral vector manufacturing, cell therapy process development and manufacturing, and biosafety testing.
The company has a history of partnering with biopharmaceutical companies to accelerate time-to-market for cell therapies, specifically T-cell therapy for solid tumour cancers.
Advanced Therapies acquired Oxford-based Oxgene in 2021 to expand its range of research and development capabilities, including proprietary plasmid discovery, Adeno-Associated Virus vector and lentiviral vector manufacturing processes.
Advanced Therapies operates five facilities across Britain and the US.
